^
    Back
    Association details:
    Biomarker:TPM3-NTRK1 fusion
    Cancer:Colorectal Cancer
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Commun
    Title:

    Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

    Published date:
    02/24/2021
    Excerpt:
    TPM3-NTRK1 fusion gene-positive KM12 colorectal cancer cells were highly sensitive to gilteritinib...
    DOI:
    https://doi.org/10.1038/s41467-021-21396-w